Utility of Chimeric Mice with Humanized Livers for Predicting Hepatic Organic Anion – Transporting Polypeptide 1B (OATP1B) – Mediated Clinical Drug-Drug Interactions

Feng, B. Liang, G. Zetterberg, C. Li, S. Huang, H. Williams, J.Gao, H. Morikawa, Y. Kumar, S.
Drug Metab Dispos. 2024 Aug 5:DMD-AR-2024-001792. doi: 10.1124/dmd.124.001792.

Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein

Kornyeyev, D. Song, Z. Eng, S. Soulette, C. Ramirez, R. Tang, J. Yue, Q. Subramanian, R. Zaboli, S. Moon, C. Tam, J. Brodbeck, J. Aggarwal, A. Diehl, L. Fletcher, S. P. Hyrina, A. Holdorf, M. M. Burdette, D.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0042024. doi: 10.1128/aac.00420-24.

Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

Das, S. Behera, P. Shewale, D. J. Bodele, J. Das, S. Karande, A. A.
Arch Virol. 2024 Apr 29;169(5):112. doi: 10.1007/s00705-024-06024-4.

Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice

Ichikawa, A. Miki, D. Hayes, C. N. Teraoka, Y. Nakahara, H. Tateno, C. Ishida, Y. Chayama, K. Oka, S.
Sci Rep. 2024 Feb 9;14(1):3362. doi: 10.1038/s41598-024-53890-8.

Hepatitis B virus evades the immune system by suppressing the NF-kappaB signaling pathway with DENND2A

Ide, M. Tabata, N. Yonemura, Y. Murai, K. Wang, Y. Ishida, A. Honda, M. Kaneko, S. Ito, S. Yanagawa, H.
Microbiol Spectr. 2024 Jan 19:e0378523. doi: 10.1128/spectrum.03785-23.

アジア太平洋肝臓学会(APASL) 2024 Kyotoでのミルテニーバイオテク株式会社主催のランチョンセミナーにて、
当社のPXBマウスを用いたアプリケーションが紹介されましたのでご案内申し上げます。

Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

Shimada, T.
Nihon Yakurigaku Zasshi. 2023;158(6):483-489. doi: 10.1254/fpj.23038.

Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers

Wang, X. Moore, M. P. Shi, H. Miyata, Y. Donnelly, S. K. Radiloff, D. R. Tabas, I.
Mol Ther Methods Clin Dev. 2023 Nov 23;31:101165. doi: 10.1016/j.omtm.2023.101165. eCollection 2023 Dec 14.

Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

Miyake, T. Mochizuki, T. Nakagawa, T. Nakamura, M. Emoto, C. Komiyama, N. Hirabayashi, M. Tsuruta, S. Shimojo, T. Terao, K. Tachibana, T.
Br J Pharmacol. 2023 Oct 23. doi: 10.1111/bph.16270.

以下学会にて、メディフォード株式会社様 (旧：株式会社ＬＳＩＭ安全科学研究所様) がPXBマウス関連の
研究発表を予定していますのでご案内申し上げます。


第97回日本薬理学会年会（神戸国際会議場・神戸国際展示場2号館）
開催日：2023年12月14日～12月16日


【詳細】
＜一般演題・ポスター＞
演題番号：1-B-P057
演題：「ヒト肝細胞キメラマウス(PXB-Mouse®)を用いた非アルコール性脂肪肝炎(NASH)モデルの開発と

演者：SHUKUROV IBROHIMJON 様（メディフォード株式会社）
日時：12月14日(木) 13:50～14:30

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy

Kashiwakura, Y. Endo, K. Ugajin, A. Kikuchi, T. Hishikawa, S. Nakamura, H. Katakai, Y. Baatartsogt, N. Hiramoto, T. Hayakawa, M. Kamoshita, N. Yamazaki, S. Kume, A. Mori, H. Sata, N. Sakata, Y. Muramatsu, S. I. Ohmori, T.
Mol Ther Methods Clin Dev. 2023 Aug 22;30:502-514. doi: 10.1016/j.omtm.2023.08.016.

2023年9月26日(火)からグランシップ(静岡県コンベンションアーツセンター)で開催されます、
日本薬物動態学会第38回年会／第23回シトクロムP450国際会議国際合同大会にて、
弊社より口演発表及び企業展示がございますのでご案内申し上げます。

また、9月25日(月)に同会場で開催の日本薬物動態学会 第16回ショートコースにて、
ランチョンセミナーを開催致しますので、重ねてご案内申し上げます。

Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials

Gane, E. Lim, Y. S. Kim, J. B. Jadhav, V. Shen, L. Bakardjiev, A. I. Huang, S. A. Cathcart, A. L. Lempp, F. A. Janas, M. M. Cloutier, D. J. Kaittanis, C. Sepp-Lorenzino, L, Hinkle, G. Taubel, J. Haslett, P. Milstein, S. Anglero-Rodriguez, Y. I. Hebner, C. M. Pang, P. S. Yuen, M. F.
J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.05.023.

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

Chida, T. Ishida, Y. Morioka, S. Sugahara, G. Han, C. Lam, B. Yamasaki, C. Sugahara, R. Li, M. Tanaka, Y. Liang, T. J. Tateno, C. Saito, T.
JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Burdette, D. Hyrina, A. Song, Z. Beran, R. K. Cheung, T. Gilmore, S. Kobayashi, T. Li, L. Liu, Y. Niedziela-Majka, A. Medley, J. Mehra, U. Morganelli, P. Novikov, N. Niu, C. Tam, D. Tang, J. Wang, J. Yue, Q. Fletcher, S. P. Holdorf, M. M. Delaney, W. E. th Feierbach, B. Lazerwith, S.
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22.

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

Zhang, S. Bastille, A. Gordo, S. Ramesh, N. Vora, J. McCarthy, E.Zhang, X. Frank, D. Ko, C. W. Wu, C. Walsh, N. Amarwani, S. Liao, J. Xiong, Q. Drouin, L. Hebben, M. Chiang, K. Chau, B. N.
PLoS One. 2022 Sep 20;17(9):e0274774. doi: 10.1371/journal.pone.0274774.

Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S
Toxicol Appl Pharmacol. 2023 Apr 15;465:116439. doi: 10.1016/j.taap.2023.116439. Epub 2023 Feb 27.

A Novel Anti-HBV Agent, E-CFCP, restores Hepatitis B virus (HBV)-induced Senescence-associated Cellular Markers Perturbation in Human Hepatocytes

Takamatsu, Y. Hayashi, S. Kumamoto, H. Imoto, S. Tanaka, Y. Mitsuya, H. Higashi-Kuwata, N.
Virus Res. 2023 Mar 23;329:199094. doi: 10.1016/j.virusres.2023.199094.

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.